MGMT and central nervous system cancer: We evaluated the clinical impact of MGMT autoantibody status and the level of the prediction of recurrence‐free survival (RFS) in 56 glioma patients with various grade (WHO grade II, n = 16; WHO grade III, n = 25; WHO grade IV, n = 15).